OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis $0.01 0.00 (-5.43%) As of 11:56 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Appili Therapeutics Stock (OTCMKTS:APLIF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Appili Therapeutics alerts:Sign Up Key Stats Today's Range$0.0108▼$0.012250-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.04Volume101,100 shsAverage Volume91,189 shsMarket Capitalization$1.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Read More… Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLIF Stock News HeadlinesSaptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of MetronidazoleMay 20, 2025 | finance.yahoo.comAppili Therapeutics Provides Update on Arrangement with Aditxt, Inc.May 19, 2025 | globenewswire.comElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.May 28, 2025 | Brownstone Research (Ad)Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to TularemiaMay 1, 2025 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZApril 28, 2025 | finanznachrichten.deAppili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™April 28, 2025 | globenewswire.comAppili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025April 2, 2025 | financialpost.comAppili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025April 2, 2025 | globenewswire.comSee More Headlines APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed this year? Appili Therapeutics' stock was trading at $0.0280 at the beginning of 2025. Since then, APLIF stock has decreased by 53.9% and is now trading at $0.0129. View the best growth stocks for 2025 here. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) posted its earnings results on Tuesday, August, 13th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2024Today5/28/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:APLIF CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.80 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-209.09% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$630,000.00 Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-0.26Miscellaneous Outstanding Shares121,266,000Free Float106,908,000Market Cap$1.56 million OptionableNot Optionable Beta-0.51 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:APLIF) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.